Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?

Albuminuria Angiotensin-Converting Enzyme Inhibitors / adverse effects Child Glomerular Filtration Rate Humans Nephritis, Hereditary / drug therapy Ramipril / adverse effects

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
06 2020
Historique:
received: 17 01 2020
accepted: 27 01 2020
entrez: 24 5 2020
pubmed: 24 5 2020
medline: 22 6 2021
Statut: ppublish

Résumé

Gross et al. present results of the EARLY PRO-TECT trial, a randomized controlled trial of ramipril versus placebo in children with early-stage Alport syndrome. Although under-enrolled and not a positive trial in the traditional sense, EARLY PRO-TECT does provide strong supportive evidence for both long-term safety and a clinical benefit of early treatment with angiotensin-converting enzyme inhibitors in slowing the progression of both albuminuria and estimated glomerular filtration rate decline in children with Alport syndrome.

Identifiants

DOI: 10.1016/j.kint.2020.01.030 PMID: 32444091
pubmed: 32444091
pii: S0085-2538(20)30147-2
doi: 10.1016/j.kint.2020.01.030
pii:
doi:

Substances chimiques

Angiotensin-Converting Enzyme Inhibitors 0
Ramipril L35JN3I7SJ

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1104-1106

Informations de copyright

Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Michelle N Rheault (MN)

Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA. Electronic address: rheau002@umn.edu.

William E Smoyer (WE)

Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations urologiques › Protéinurie › Albuminurie › Long-term ACE inhibition in Alport syndrome:...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéases › Inhibiteurs de l'enzyme de conversion de l'angiotensine › Long-term ACE inhibition in Alport syndrome:...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Long-term ACE inhibition in Alport syndrome:...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques des voies urinaires › Débit de filtration glomérulaire › Long-term ACE inhibition in Alport syndrome:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Long-term ACE inhibition in Alport syndrome:...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies du tissu conjonctif › Maladies du collagène › Néphropathie familiale avec surdité › Long-term ACE inhibition in Alport syndrome:...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Ramipril › Long-term ACE inhibition in Alport syndrome:...